1. Home
  2. GERN vs GRC Comparison

GERN vs GRC Comparison

Compare GERN & GRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • GRC
  • Stock Information
  • Founded
  • GERN 1990
  • GRC 1933
  • Country
  • GERN United States
  • GRC United States
  • Employees
  • GERN N/A
  • GRC N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • GRC Fluid Controls
  • Sector
  • GERN Health Care
  • GRC Industrials
  • Exchange
  • GERN Nasdaq
  • GRC Nasdaq
  • Market Cap
  • GERN 840.7M
  • GRC 931.3M
  • IPO Year
  • GERN 1996
  • GRC N/A
  • Fundamental
  • Price
  • GERN $1.18
  • GRC $37.45
  • Analyst Decision
  • GERN Buy
  • GRC
  • Analyst Count
  • GERN 9
  • GRC 0
  • Target Price
  • GERN $5.13
  • GRC N/A
  • AVG Volume (30 Days)
  • GERN 11.5M
  • GRC 70.8K
  • Earning Date
  • GERN 05-07-2025
  • GRC 04-24-2025
  • Dividend Yield
  • GERN N/A
  • GRC 1.98%
  • EPS Growth
  • GERN N/A
  • GRC 21.97
  • EPS
  • GERN N/A
  • GRC 1.69
  • Revenue
  • GERN $116,293,000.00
  • GRC $664,347,000.00
  • Revenue This Year
  • GERN $194.54
  • GRC $4.76
  • Revenue Next Year
  • GERN $56.51
  • GRC $4.50
  • P/E Ratio
  • GERN N/A
  • GRC $22.14
  • Revenue Growth
  • GERN 22264.04
  • GRC 0.92
  • 52 Week Low
  • GERN $1.17
  • GRC $30.87
  • 52 Week High
  • GERN $5.34
  • GRC $43.79
  • Technical
  • Relative Strength Index (RSI)
  • GERN 32.46
  • GRC 63.21
  • Support Level
  • GERN $1.34
  • GRC $36.18
  • Resistance Level
  • GERN $1.44
  • GRC $37.25
  • Average True Range (ATR)
  • GERN 0.10
  • GRC 0.96
  • MACD
  • GERN 0.00
  • GRC 0.39
  • Stochastic Oscillator
  • GERN 3.23
  • GRC 90.05

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.

Share on Social Networks: